After Cassava Sciences announced top-line results from its Cognitive Maintenance Study with simufilam, H.C. Wainwright said the results were “positive,” as they showed treatment with simufilam for 18 months stabilized cognition in patients with mild Alzheimer’s disease, or AD, and argues that the data “further support” simufilam’s potential to modify Alzheimer’s disease progression. The firm, which views simufilam’s potential to change the way AD is treated as “underappreciated,” reiterates a Buy rating and $124 price target on Cassava shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SAVA:
- Cassava Sciences Plunges despite Solid Drug Study
- Cassava’s simufilam didn’t slow cognitive decline, STAT’s Feuerstein says
- Cassava says oral simufilam slowed cognitive decline in withdrawal trial
- Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
- New Research Shows Simufilam Suppresses Overactive mTOR